Quoin Raises Up To $50 Million to Fund QRX003, Extending Runway into 2029
Aug 28, 2026, 6:06 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Dilution from issuing 6.3 million ADSs and 3.15 million warrants likely exerts near-term pressure on QNRX. Warrants with a $6.10 strike add potential for future dilution if exercised, depending on share price. However, the deal improves financial flexibility and funding for QRX003 milestones, which can be a longer-term positive if milestones are met.
AI summary
What happened, with direct paths to the underlying reporting
Quoin Pharmaceuticals announced a private placement to raise up to $50 million, with about $30.8 million upfront and up to $19.2 million via warrants. It will issue 6,305,300 ADSs and 3,152,650 accompanying warrants at $4.88 per ADS, with a $6.10 exercise price and a five-year expiry. Proceeds will fund QRX003 development for Netherton Syndrome and general corporate needs, extending the company’s cash runway into the second half of 2029.
Quoin to raise up to $50M via private placement. Upfront funding about $30.8M.
ADSs: 6,305,300; accompanying warrants: 3,152,650; price per ADS $4.88.
Warrants exercisable at $6.10; expiry five years post-closing.
Private placement closes around Aug 31, 2026; proceeds fund QRX003 and run to 2029.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
